Design Therapeutics Inc
NASDAQ:DSGN
Intrinsic Value
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of DSGN.
Fundamental Analysis
Balance Sheet Decomposition
Design Therapeutics Inc
Current Assets | 284.6m |
Cash & Short-Term Investments | 281.8m |
Receivables | 1.4m |
Other Current Assets | 1.4m |
Non-Current Assets | 5.1m |
PP&E | 4.6m |
Other Non-Current Assets | 430k |
Current Liabilities | 9.6m |
Accounts Payable | 1.9m |
Accrued Liabilities | 7.7m |
Non-Current Liabilities | 2.3m |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
Design Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-78.2m
USD
|
Operating Income
|
-78.2m
USD
|
Other Expenses
|
11.3m
USD
|
Net Income
|
-66.9m
USD
|
Free Cash Flow Analysis
Design Therapeutics Inc
What is Free Cash Flow?
DSGN Profitability Score
Profitability Due Diligence
Design Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Design Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
DSGN Solvency Score
Solvency Due Diligence
Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DSGN Price Targets Summary
Design Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for DSGN is 4.85 USD with a low forecast of 4.04 USD and a high forecast of 6.3 USD.
Ownership
DSGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DSGN Price
Design Therapeutics Inc
Average Annual Return | -24.39% |
Standard Deviation of Annual Returns | 40.79% |
Max Drawdown | -95% |
Market Capitalization | 220.8m USD |
Shares Outstanding | 56 002 000 |
Percentage of Shares Shorted | 8.47% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.